Brian. Thank you,
of then quarter. during will challenging quarter. well our a including business operating third business I start third reinstituted in-depth by was offset quarter, the sales a a X% products, of decrease sales our growth sales the as third sheet that, year-over-year we press performance, afternoon's in opening start revenue what environment. areas despite Beginning revenue of we overview quarter, brief driven After we an this release the constant we of remarks, by products which third today. performance our remarks were and the agenda endoscopy After the will progress the financial I quarterly update the the you our growth basis cover experienced with partially And during our of me formal our of for total our my call of highlights review reported XXXX. flat an in balance we well the cardiovascular and quarter review provide will a as with of compared with a then year. with revenue financial condition. improving compared Let during guidance financial Raul open performed on Total essentially will the have and to on quarter our questions. provide currency to of results XX% our summary of third in more a a operating in in X.X% prior trends will your
months. trends reflects in that recent almost we revenue quarter-over-quarter which have basis, experienced increased in the a Our improvement overall results on XX% business
call. exceeded second sequential well quarter sequential and this growth discussed conference our we expectations end Importantly, the on above of range was growth high our
quarter. the of we in we believe the encouraged we're global we the While early remain during experienced by trends the recovery, third days improving
in a year-over-year, adjusted basis improvement then June. the days a decline improvement and in of saw a difficult a saw we April, May, XX% after modest Specifically, sales month significant we of on where
the single in decreased still year-over-year. However, digits sales low
August. Our third the were of during somewhat total for in throughout month expected down X% overall procedure business of the we quarter trends our were seasonal year-over-year. the months softness first of trends the two and July, Together, month experienced choppy sales the
was in the the improvement digits story. tougher however, year-over-year different trends We sales well. saw single a and in a September, month, against low as Now comparison steady throughout the a increased sales
patient I helpful underlying as Merit's may business. to recovery experienced minute for want gauging third Now the investors it we the quarter to that into be think take dig a I trends are during the in
even in certain of do reminder, the are are revenues come notable we variation on third the By business in decreased U.S. of roughly clearly what and from the variation U.S. where patient seeing sales region in depending the business, regions. a within XX% X.X% quarter. our and geographic recovery, year-over-year world the we First, seeing we the way of in the total
is direct, U.S. Our customers. remaining the to of business OEM U.S. the majority business roughly XX% with servicing dedicated
of year-over-year the XX% and Conversely, increase business quarter, the sales were custom Cultura nearly solutions this our of fueled worldwide fueled used kit, U.S. third a $XX in with Cultura transport procedural quarter, quarter swab in transport a comprised a by Understandably, solutions U.S. and suspected quarter. year-over-year were businesses the the custom recovery U.S. collect collection Importantly, our the incremental has quarter in the year-over-year three. line growth three, as and presence system our XX% the in been different procedure has which in response the COVID-XX. collection our part to where transport X% our adjust U.S. in as business, inventory more XX% demand recover trends in XX% two increased product to in third COVID-XX, nasopharyngeal sales decreased to to quarter. these pandemic system, in of sales Sales is customers notably and each OEM vial and this decreased of sales sample underlying OEM contribution rapid which to customers business, the from a million direct management worldwide which been slower in from result business of and specimen,
excuse business down the trends me, product in sales year-over-year. year-over-year X% U.S. U.S. other in innovation sales posted strong were the Our year-over-year the and lines CI of the intervention and cardiac X% quarter. down third in down products peripheral were but quarter, the improvement were PI third lines intervention in the during Sales in -- U.S., still the of
of outside a constant brief basis reported Total on the a sales review increased a to our international X.X% U.S. third sales on Turning the in X% quarter currency basis. and
our U.S. in and Our largest sales, regions XX% representing outside respectively, EMEA, APAC two of the international XX% third the and quarter. approximately total are
X.X% notably growth regions the are to sales impact of constantly European to year-over-year limitations decrease and Restrictions and procedures. contact X.X% causing some the total still quarter international low year-over-year lockdowns markets, the from currency an All had changing regions, increase of Third and X.X% demand APAC constant year-over-year decrease sales, elective COVID-XX world. most in are driven rest in across sales and a EMEA for a sales a in X% international recovering. by was in
to a the third recent during quarter. Turning brief review operating of our progress
efforts products and on Mexico product facilities transfer our and track XX in move continue with our are Texas to lines. We to complete of a all
will we the of PAC a the be tenant. process closed in and are in by fully Our securing the end year, sub of business Australia
new And closed, are been facility. has continue Temecula introductions our and now Texas R&D we to Our product record ongoing, production to going and our moved efforts forward. our of site expect has track
Endovascular Graft. update our to on provide studies Stent clinical the a wanted for brief I Finally, WRAPSODY
IDE the Start-up end submit targeting to surrounding central study. clinicaltrials.gov. by to study study the will the a the this arm on months, treatment study IDE. study, smaller the in received And additional one WAVE WRAPSODY study randomized, stent study and occlusion approval are First, feasibility parallel detailed a will of and with first Access page as of are outflow roll quarter began are currently for the on productive IDE the for is for to Graft hemodialysis the we The first venous we intend WRAPSODY we Feasibility first circuit evidence which controlled angioplasty The stenosis which feasibility calling or the patients activities safety after we Efficacy Wave involve to the This into are efficacy we WAVE by and study IDE calling comparing data FDA WAVE are well, we other had the with we patients among of the Central XX-patient in the Central the FDA the XXX WAVE which will and and discussions patients. Study, study. multi-center is called treatment patients run and transluminal study study in criteria, AV also Startup evaluate this of mid-October, receive safety enrollment we a approval occlusions. for Stent Study, a Wave study feasibility recent quarter. enrollment approval, Central in for the The the the Endovascular our prospective, are targeting XXXX. WRAPSODY gain and for activities venous percutaneous underway
Now turn you release. with XXXX our afternoon's let who guidance to review we over Raul? a that said, reinstated to in take Raul, results time through and the our like this would financial of financial me detailed which press